Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Ravulizumab Treatment Outcomes in Patients With Generalized Myasthenia Gravis (gMG) Naive to Complement Inhibitors. Prospective, Multicenter, Non-interventional Study (MG-ARCADIA).

NCT06909253 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT06909253
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06909253 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Ravulizumab Treatment Outcomes in Patients With Generalized Myasthenia Gravis (gMG) Naive to Complement Inhibitors. Prospective, Multicenter, Non-interventional Study (MG-ARCADIA).
Lead sponsor
AstraZeneca
Phase
Observational
Overall status
Recruiting
Start date
May 15, 2025
Completion date
December 31, 2029
Enrollment
50 (estimated)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

myasthenia gravis, generalized